Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The challenge of limited vaccine supplies: impact of prior infection on anti-spike IgG antibody trajectories after a single COVID-19 vaccination

View ORCID ProfileJia Wei, Philippa C. Matthews, View ORCID ProfileNicole Stoesser, Ian Diamond, Ruth Studley, Emma Rourke, Duncan Cook, John I Bell, John N Newton, Jeremy Farrar, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, David W. Eyre, Koen B. Pouwels, the COVID-19 Infection Survey team
doi: https://doi.org/10.1101/2021.12.08.21267353
Jia Wei
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jia Wei
Philippa C. Matthews
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
3The Francis Crick Institute, 1 Midland Road, London, UK
4Division of infection and immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Stoesser
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
6The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
7The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicole Stoesser
Ian Diamond
8Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Studley
8Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Rourke
8Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan Cook
8Office for National Statistics, Newport, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John I Bell
9Office of the Regius Professor of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John N Newton
10Health Improvement Directorate, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy Farrar
11Wellcome Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison Howarth
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian D. Marsden
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
12Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Hoosdally
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Yvonne Jones
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David I Stuart
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derrick W. Crook
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
6The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
7The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim E. A. Peto
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
6The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
7The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Sarah Walker
1Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
6The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
13MRC Clinical Trials Unit at UCL, UCL, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Eyre
2Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK
5Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
6The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
7The National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koen B. Pouwels
6The National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK
14Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: koen.pouwels@ndph.ox.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Given high SARS-CoV-2 incidence, coupled with slow and inequitable vaccine roll-out, there is an urgent need for evidence to underpin optimum vaccine deployment, aiming to maximise global population immunity at speed. We evaluate whether a single vaccination in previously infected individuals generates similar initial and subsequent antibody responses to two vaccinations in those without prior infection. We compared anti-spike IgG antibody responses after a single dose of ChAdOx1, BNT162b2, or mRNA-1273 SARS-CoV-2 vaccines in the COVID-19 Infection Survey in the UK general population. In 100,849 adults who received at least one vaccination, 13,404 (13.3%) had serological and/or PCR evidence of prior infection. Prior infection significantly boosted antibody responses for all three vaccines, producing a higher peak level and longer half-life, and a response comparable to those without prior infection receiving two vaccinations. In those with prior infection, median time above the positivity threshold was estimated to last for >1 year after the first dose. Single-dose vaccination targeted to those previously infected may provide protection in populations with high rates of previous infection faced with limited vaccine supply, as an interim measure while vaccine campaigns are scaled up.

Competing Interest Statement

DWE declares lecture fees from Gilead, outside the submitted work. No other author has a conflict of interest to declare.

Funding Statement

This study is funded by the Department of Health and Social Care with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. JW is supported by University of Oxford and the China Scholarship Council. ASW, TEAP, NS, DE, KBP are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance (NIHR200915), a partnership between the UK Health Security Agency (UKHSA) and the University of Oxford. ASW and TEAP are also supported by the NIHR Oxford Biomedical Research Centre. KBP is also supported by the Huo Family Foundation. ASW is also supported by core support from the Medical Research Council UK to the MRC Clinical Trials Unit [MC_UU_12023/22] and is an NIHR Senior Investigator. PCM is funded by Wellcome (intermediate fellowship, grant ref 110110/Z/15/Z) and holds an NIHR Oxford BRC Senior Fellowship award. DWE is supported by a Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. NS is an Oxford Martin Fellow and holds an NIHR Oxford BRC Senior Fellowship. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health and Social Care, or UKHSA. For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are still being collected for the COVID-19 Infection Survey. De-identified study data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. For further information about accreditation, contact Research.Support@ons.gov.uk or visit the SRS website.

https://www.ons.gov.uk/aboutus/whatwedo/statistics/requestingstatistics/approvedresearcherscheme

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 08, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The challenge of limited vaccine supplies: impact of prior infection on anti-spike IgG antibody trajectories after a single COVID-19 vaccination
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The challenge of limited vaccine supplies: impact of prior infection on anti-spike IgG antibody trajectories after a single COVID-19 vaccination
Jia Wei, Philippa C. Matthews, Nicole Stoesser, Ian Diamond, Ruth Studley, Emma Rourke, Duncan Cook, John I Bell, John N Newton, Jeremy Farrar, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, David W. Eyre, Koen B. Pouwels, the COVID-19 Infection Survey team
medRxiv 2021.12.08.21267353; doi: https://doi.org/10.1101/2021.12.08.21267353
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The challenge of limited vaccine supplies: impact of prior infection on anti-spike IgG antibody trajectories after a single COVID-19 vaccination
Jia Wei, Philippa C. Matthews, Nicole Stoesser, Ian Diamond, Ruth Studley, Emma Rourke, Duncan Cook, John I Bell, John N Newton, Jeremy Farrar, Alison Howarth, Brian D. Marsden, Sarah Hoosdally, E Yvonne Jones, David I Stuart, Derrick W. Crook, Tim E. A. Peto, A. Sarah Walker, David W. Eyre, Koen B. Pouwels, the COVID-19 Infection Survey team
medRxiv 2021.12.08.21267353; doi: https://doi.org/10.1101/2021.12.08.21267353

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1778)
  • Dentistry and Oral Medicine (240)
  • Dermatology (173)
  • Emergency Medicine (317)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10834)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2968)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1938)
  • Health Policy (837)
  • Health Systems and Quality Improvement (747)
  • Hematology (295)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12535)
  • Intensive Care and Critical Care Medicine (697)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2819)
  • Nursing (152)
  • Nutrition (435)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (259)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (382)
  • Pediatrics (870)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (341)
  • Psychiatry and Clinical Psychology (2653)
  • Public and Global Health (5393)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (599)
  • Respiratory Medicine (729)
  • Rheumatology (330)
  • Sexual and Reproductive Health (294)
  • Sports Medicine (280)
  • Surgery (329)
  • Toxicology (48)
  • Transplantation (151)
  • Urology (127)